fig1

Figure 1. ACHIEVE-3 outcomes at week 52. (A) mean HbA1c change from baseline (%) with orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, and oral semaglutide 14 mg; (B) mean body-weight change from baseline (%) in the same treatment groups; (C) percentage of participants who discontinued study treatment because of GI adverse events. (A and B) show treatment-regimen estimand means. The prespecified HbA1c comparisons and 95%CIs are reported in the text. Figure created by the authors from numerical data reported by Rosenstock et al. in ACHIEVE-3^[8,9]. Error bars in (A and B) represent SE. CI: Confidence interval; GI: gastrointestinal; HbA1c: glycated hemoglobin; SE: standard error.